The correlation between the pharmacist time required for counseling patients and the characteristics of the services provided was studied.
H
ealth insurance companies, government programs such as Medicaid, and many health maintenance organizations (HMOs) contract with prescription benefit management systems, chain drugstores, and independent pharmacies for the dispensing of prescription drugs to their members. The payments made to dispensing pharmacies are commonly based on the cost of the medication dispensed (ingredient costs), plus a standard dispensing fee to cover the routine pharmaceutical services and overhead required to stock and dispense the drug. These fees may be established unilaterally by the payer (e.g., Medicaid) or may be set through contract negotiations. However, few payment systems specify a range of dispensing fees designed to reimburse pharmacists for nonroutine patient-counseling services. As a result, pharmacists are discouraged from providing more intensive counseling to patients. 1 Health insurance companies and HMOs may be willing to pay for nonroutine pharmacist consultations if these services prove to be effective in reducing health care costs and improving drug therapy outPharmacist time requirements for counseling in an outpatient pharmacy
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comes. Payment systems for professional pharmacy services must be built on the payers' experience with systems designed to pay for other health care services. Therefore, special attention must be paid to the problems that have affected these reimbursement systems in the past. Medicare's system for reimbursing physicians for their services provides a useful point of reference. The Medicare billing codes for physician services are designed to reflect the amount of time required to provide each service. For example, physician office and outpatient visits are covered by 10 billing categories that depend on the status of the patient (i.e., new versus established), the comprehensiveness of the history and treatment required during the visit, and the complexity of the medical decisions. 2 This approach has several well-recognized limitations. First, the categories covering physician services are often difficult to verify, be-cause the payer cannot confirm the comprehensiveness and complexity of the specific services provided. In the case of office visits, the payer can verify the patient's status, but the comprehensiveness of the history and treatment required during the visit cannot be easily quantified. As a result, some physicians overcharge payers by using codes for more involved office visits than actually took place. 3, 4 Historically, physician fees have been set on the basis of criteria defining usual, customary, and reasonable fees. After 25 years of operation, Medicare found it necessary to establish a prospective fee schedule based on the estimated resource cost associated with physician services. 5 This schedule was needed to correct the inequalities and fee inflation inherent in a "usual, customary, and reasonable" pricing system. 6 Any resource-based fee system must be continually updated, however, to reflect technological change, inflation, and supply and demand. 7 The number of payment codes currently specified for medical services complicates strategies for controlling physicians' responses to changes in the payment system and for setting fee levels through competitive pricing systems. 8, 9 For example, Medicare has invested in research designed to bundle physician services into units based on episodes of care or episodes of illness in an effort to avoid misrepresentation of services delivered and provision of unnecessary services to compensate for reductions in fees. [10] [11] [12] Given the history associated with payment for physician services, a feefor-service system for pharmacist counseling must meet the following criteria to be acceptable to both pharmacists and insurers:
1. Specific units of service must be defined that reflect the cost of pharmacist time used for providing the service.
2. The payer must be able to verify which services were provided. 3. The number of distinct pharmacist counseling services defined for payment must be limited to facilitate fee negotiations.
We used data from the Kaiser Permanente/USC Patient Consultation Study 13 to investigate the feasibility of creating a payment system for pharmacist counseling that meets these criteria. Pharmacist-patient encounter data, including the type of problems encountered, the actions taken, the disposition of the prescription, and a self-report of the time required to complete the counseling, were collected at the time of dispensing. We then investigated the relationship between the characteristics of the encounters and pharmacist time. Specific attention was paid to differentiating between those clusters of problems, actions, and dispositions (PADs) that constituted a routine encounter and PADs for which a separate fee could be justified because of increased pharmacist time requirements.
Background
The estimated cost of morbidity and mortality resulting from inappropriate medication use exceeded $177.4 billion in the United States in 2000. 14 Bates et al. 15 found that adverse drug events (ADEs) were common and often preventable, and Dobie and Rascati 16 reported that interventions by community pharmacists to correct prescribing errors added clinical and economical value to patient care. Given these results, it is not surprising that the 1999 Institute of Medicine report on medical mistakes, 17 although controversial, [18] [19] [20] focused on the frequent and preventable nature of medication errors that result in poor patient outcomes and increased health care costs.
Inappropriate medication use can take several forms: prescribing problems (e.g., inaccurate dosing, drugdrug and drug-food interactions), monitoring problems (lack of monitoring for adverse effects and treatment efficacy), and drug administration problems (incorrect administration times, missing doses, overdoses). 21 These drug-related problems have significant clinical and economical impacts. For example, patient noncompliance with medications is responsible for almost 10% of all hospital admissions, 23% of all nursing-home admissions, and the loss of 20 million workdays each year. 22, 23 Pharmacists are increasingly involved in improving patient care, in part because of the growth of managed care organizations that have a financial incentive to reduce the frequency of preventable ADEs and noncompliance. Under managed care, pharmacists have expanded their functions to include reviewing drug therapies for appropriateness, monitoring patients' responses to therapy, and counseling patients about compliance, potential drug interactions, and other matters. 24 Many health care organizations and managed care plans have supported the provision of specialized pharmaceutical services, such as pharmacist-run clinics for patients with hypertension, asthma, and diabetes. [25] [26] [27] Pharmacist recommendations not only improve patients' quality of life but also save money. [28] [29] [30] [31] [32] Pharmacists can improve drug therapy outcomes by ensuring efficacy, minimizing toxicity, and increasing patient compliance. 21 Since the pharmacy is generally a patient's last point of contact with the health system before using a medication, pharmacists are the last line of defense against medication mistakes.
31, 33 Galt et al. 34 found that 86% of patients wanted to discuss medication-related problems with a pharmacist and that 58% desired formal visits.
Several studies have evaluated the pharmacist's role in decreasing ADEs and treatment costs. Rupp 35 observed that pharmacists can identify potential medication problems, and Munroe et al. 21 used data from the community pharmacy setting to show that disease management by pharmacists decreased the total monthly health care cost. Borgsdorf et al. 36 conducted a study in which pharmacists reviewed all medications with patients and changed, if needed, some aspects of therapy; the interventions significantly reduced the number of unscheduled physician visits, urgent care visits, and emergency-room visits. Finally, a study by Knapp et al. 37 found that pharmacist recommendations resulting in prescription changes decreased costs by an average of 65.8%.
Although counseling by pharmacists is effective in lowering overall costs and patient morbidity and mortality, this service is generally not compensated when a managed care organization contracts with community pharmacies for dispensing. Hence, pharmacies often lose money if extra time is spent on counseling. In addition, staffing in pharmacies is often based on the number of prescriptions filled and dispensed rather than time spent on direct patient care.
Methods
Setting. The Kaiser Permanente/ USC Patient Consultation Study was conducted in Kaiser Permanente's (KP's) southern California region between 1992 and 1995. 13 KP provides prepaid comprehensive health care services to 2.2 million members, including pharmaceutical services through a total of 107 pharmacies employing approximately 600 pharmacists. Each pharmacy was assigned to provide one of three models of pharmacist counseling: (1) counseling for each new or changed prescription, as mandated by California state law (state model, 67 pharmacies), (2) counseling focused on selected high-risk ambulatory care patients (KP model, 20 pharmacies), and (3) counseling provided on demand or when deemed necessary (control model, 20 pharmacies). The care provided under the control model was similar to that given before counseling was mandated by law in California. The control pharmacies were not provided any additional personnel resources and thus could not implement counseling beyond that traditionally offered.
Data collection. The Kaiser Permanente/USC Patient Consultation Study was designed primarily to investigate the impact of counseling by pharmacists on patient satisfaction, health-related quality of life, and health care utilization. The results for the primary outcomes have been reported elsewhere. 28, 30, 32 This study used secondary data, which included the time required to provide counseling under each model. Under all three models, pharmacists were asked to document any counseling that required action beyond what was specified for the model to which they were assigned. An encounter form was completed for each episode of counseling that met the reporting requirements of the study ( Figure 1 ). Recorded were the potential problem addressed by the counseling session, the action taken to resolve the problem, and the disposition of the prescription after the problem was resolved. The prescription number, date, time required, and pharmacist initials were also recorded.
The requirement that pharmacists provide data only for encounters that necessitated action beyond the assigned model was intended to minimize the impact of data collection on counseling, especially for statemodel pharmacies that were legally required to provide counseling for each new or changed prescription. These various reporting requirements resulted in a mix of encounters by model type. For example, most counseling sessions that required referrals were defined as exceptional for all three models, and an encounter form was required. Under the control model, the pharmacist was required to document counseling provided at his or her discretion or in response to a patient's request. Therefore, it was likely that controlmodel pharmacists reported the time required to provide even routine patient counseling. Pharmacists under the state model were asked to document counseling that exceeded the provision of basic drug information for any new or changed prescription.
Reports from state-model pharmacies were likely, therefore, to involve problems easily identified by the pharmacists, such as problems related to dosage and quantity dispensed. Lastly, pharmacists under the KP model were required to document only focused, comprehensive counseling for high-risk patients that significantly exceeded the routine actions specified in the counseling grids. 13 These encounters were likely to involve more substantial problems, such as those related to adverse effects and drug interactions.
Data analysis. Potential reporting bias. The different reporting requirements for the three models introduced the potential for reporting bias across models. If such a bias existed, then the self-reports of pharmacist time required to provide counseling related to a specific PAD would vary across models. To investigate this, the time requirements were compared for the three most frequently reported PADs. Once these frequent PADs were identified, the mean pharmacist time per PAD was compared by model and across the three PADs by using two-way analysis of variance (ANOVA).
Intervention time. To be acceptable to payers, any fee-for-service reimbursement system for counseling by pharmacists must specify a limited number of services that are verifiable and reflect the cognitive services provided. To be acceptable to pharmacists, this system must cover the most common types of counseling required in an outpatient pharmacy setting, be relatively easy to administer, and reflect the significant differences in the time required to provide each type of counseling. Therefore, our analysis reduced the universe of 300 individual PADs implicit in the data collected by the Kaiser/USC Patient Consultation Study to a workable number of categories that reflected the services provided and the pharmacists' time inputs.
One approach was to bundle the 300 PADs into a handful of PADs that required significantly more pharmacist time than the more routine consultations. In this way, the pharmacist need only document, and the payer verify, a limited number of claims for payment over and above a standard dispensing fee. To facilitate validation by the payer, these PADs should be relatively homogeneous with respect to the type of counseling provided. For example, PADs involving only physician contact should not be combined with PADs involving only extended direct interaction with the patient. Identifying these homogeneous PADs in the KP data required several steps. First, mean pharmacist time was derived for each category of potential PAD listed on the encounter form in order to aggregate subcategories that involved similar activities and similar average time requirements. Next, these aggregated subgroups were used to investigate whether possible links existed between problem-action, action-disposition, and dispositionproblem pairs. For example, if actions involving patient contact were highly correlated with the prescription being dispensed as written, then the PAD payment clusters could be simplified by dropping the three possible disposition categories as potential modifiers for payment for counseling requiring patient contact. Finally, a series of regression models were used to analyze the correlation between the time required for counseling and the simplified list of potential PAD payment categories. The variables in the regression analysis included interaction terms between simplified PAD categories with more than 100 observations. The regression results were used to identify which PADs were associated with significant increases in pharmacist time, since these PADs could require an incremental fee in addition to the routine dispensing fee. The regression models were estimated by using the Statistical Analysis Software (SAS) System for Windows, version 6.12 (SAS Institute, Cary, NC).
Results
Descriptive statistics. A total of 28,615 observations were collected over the two-year period of the Kaiser Permanente/USC Patient Consultation Study. The encounter forms with missing or incomplete data were not included in the analy- sis, as were forms for any encounters lasting more than 60 minutes (0.1% of the observations). The final data set consisted of 20,547 observations. Data on the frequency of PADs for the three models of pharmacist counseling are provided in Table 1 . Appropriateness of therapy (e.g., dosage, directions, and quantity) was the most frequently reported problem area for the state model (77.7%) and the control model (75.4%); this was expected, since problems related to appropriateness are routinely detected at the time of dispensing. Conversely, the KP model focused on more clinical services, such as monitoring (43.8%) and preventing drug interactions (30.7%).
Problems related to drug therapy monitoring and drug interactions require collecting information from the patient. It follows, then, that patient contact was the most frequently reported action taken under the KP model (64.8%). Similarly, a prescription cannot be legally filled without resolving problems related to appropriateness of therapy, and physicians alone can alter dosage, quantity, and duration. Physician acceptance or modification of the pharmacist recommendation was the most frequently reported action under the state (56.6%) and control (36.3%) models.
Data on the disposition of the prescriptions were consistent with the problems identified and actions taken across the three models. For example, problematic prescriptions (e.g., inaccurate drug or dosage) were frequently changed before dispensing under the state model (76.3%) and the control model (55.5%). Prescriptions were much more likely to be dispensed as written under the KP model, once the pharmacist had taken action to monitor therapy or prevent drug interactions.
Reporting bias. Systematic differences in the reporting of pharmacist time requirements may have existed across the three models of pharmacist counseling. The presence of systematic differences would call into question the validity of combining data across models in an effort to determine the relationship between the characteristics of the counseling and pharmacist time. To investigate this, the three most frequently reported PADs were identified and the mean pharmacist time required for the encounters was compared across models and across PADs by using two-way ANOVA ( Table 2 ). The three PADs used in the analysis constituted 33% of all PADs available for analysis. The mean time for PADs 1 and 2 did not differ significantly by type of model, while the mean time for PAD 3 differed significantly across models (p < 0.05). The latter difference may be spurious, however, given the very low frequency of this PAD for the state and control models. Equally important, for each model the mean time across the three PADs differed significantly (p < 0.05), suggesting that payments for these service clusters should also vary. We proceeded with our analysis by aggregating the encounter data across models, knowing that reporting bias across models for similar PADs cannot be fully discounted.
Pharmacist time. Table 3 presents the mean pharmacist time required for the services provided. These data were used to combine PAD categories based on observed differences across categories and frequency of occurance. Statistical tests for differences across PADs were derived using regression analysis. The mean ± S.D. time for all problems related to appropriateness of therapy was 4.9 ± 5.4 minutes, including 4.7 ± 4.2 minutes for problems related to quantity dispensed or duration of therapy a KP = Kaiser Permanente. b Identity of pharmacy not recorded. and 5.1 ± 5.9 minutes for problems related to dosage form or route of administration. This narrow range suggests that all four appropriateness subcategories can be aggregated for reimbursement purposes. For monitoring, problems related to adverse effects and toxicity required much more pharmacist time (5.4 ± 5.1 minutes) than problems related to duplicate therapy or noncompliance (2.9 ± 2.7 and 3.7 ± 3.6 minutes, respectively). This was not surprising, as the time required to assess adverse effects and symptoms of toxicity exceeds that required to assess compliance or check for duplicate therapies. However, problems related to adverse effects and toxicity represented only 9.5% of all monitoring-related problems (unpublished data). As a result, the three categories of monitoring problems were aggregated into a single category in the subsequent analysis. Similarly, the problem subgroups related to drug interactions were aggregated into a single subcategory because of the similar time requirements for the two interaction problems that dominated this category. These included drug-drug interactions and allergy or sensitivity problems, which constituted 97% of all reported problems related to drug interactions (unpublished data). The aggregation of subcategories of actions for resolving problems was more complicated. The subcategories of actions requiring physician contact were divided into subgroups depending on resolution, since more time was required when a physician accepted, rejected, or modified the pharmacist's recommendation (5.7 ± 5.7 minutes) than when the physician simply provided clarification (4.3 ± 5.1 minutes). The category of action involving a physician communication form being completed by Significant difference across models (p < 0.0001). the pharmacist was retained as a separate category because of the pharmacist time involved and the fact that this action was specific to the KP system. We did not want data from these encounters confounding measurement of the time impact of more generic action categories in the regression analysis described below. The subcategories of actions requiring patient contact should, in theory, reflect similar pharmacist time requirements, since the patient is usually readily available at the time of dispensing. The data in Table 3 confirm these expectations. Finally, mean pharmacist time varied markedly across the three types of referrals listed in Table 3 . However, patient referrals were relatively rare events, and referrals to pharmacy-based clinic and member health education may not exist outside of a closedpanel HMO system. Therefore, for simplicity, only a single referral category was used to define PADs in the regression analysis.
Disposition of the prescription included only three categories, for which the pharmacist time requirements differed markedly (Table 3) . The disposition was highly correlated with the action taken to resolve the problem (Spearman correlation coefficient, 0.70). This made it possible to further reduce the number of potential PAD payment clusters by simply dropping disposition as a factor in describing counseling for reimbursement purposes.
The final step in analyzing the pharmacist time requirement was to estimate a regression model of pharmacist time with which to identify the problem-action clusters that required significantly more time. The model specified dummy variables for potential problems (monitoring was the reference category), actions taken (physician clarification was the reference category), and selected interaction terms involving the problem and action categories. Of all possible interaction terms involving these two types of variables, only frequently occurring (n > 100) interaction terms were added to the final regression model. A list of all possible interaction terms and their frequencies is provided in Table 4 . A stepwise regression procedure was used to determine which of these interaction terms were correlated with significant increases or reductions in pharmacist time requirements. The final regression model is reported in Table 5 .
The average patient contact took approximately 3 minutes for the reference group (defined as encounters involving problems related to drug therapy monitoring (P 2 ) and patient contact (A 4 ) [the intercept term in Table 5 ]). Overall, problems related to appropriateness of therapy (P 1 ) required 1.8 more minutes than monitoring problems, while problems involving drug interactions (P 3 ) required an additional 0.5 minute, independent of the actions taken to resolve the problems. Among the action categories, the least time relative to patient contact (A 4 ) was required for referral (2.5 additional minutes for A 5 ), followed by physician clarification (2.6 additional minutes for A 3 ). When the provider was contacted, the amount of time varied, depending on whether the physician accepted, rejected, or modified the pharmacist's recommendation (3.7 additional minutes for A 1 ) or simply provided a clarification (2.6 additional minutes). Counseling that led the pharmacist to refer the patient back to the physician, a specialty clinic, or patient education took an additional 2.5 minutes.
The incremental time periods required for different classifications of problems and actions were not strictly additive, as indicated by the significant coefficients for the interaction variables. For example, the estimated regression coefficient for the interaction term for appropriateness of therapy problems (P 1 ) requiring a physician response to the recommendation (A 1 ) was -3 minutes, ina P = problem, A = action. dicating that this problem-action cluster required 3 minutes less than indicated by simply adding the marginal time requirements for P 1 (1.8 minutes) and A 1 (3.7 minutes). Using the data from Table 5 , mean intervention time was calculated for the 15 possible problem-action clusters (Table 6 ). For instance, the estimated intervention time for an appropriateness of therapy problem (P 1 ) requiring a physician decision (A 1 ) was calculated by adding the following parameter estimates from Table 5 : intercept (2.9 minutes) + P 1 (1.8 minutes) + A 1 (3.7 minutes) + P 1 A 1 (-3.0 minutes) = 5.4 minutes. The data in Table 6 can readily be converted to estimates of the cost of pharmacist time. For example, if one assumes an hourly wage rate of $50 and a 33% fringe benefit rate (the approximate cost of a pharmacist in our employment setting), the cost per minute of pharmacist time is approximately $1.11. Under this set of assumptions, the estimated cost of counseling involving a problem of therapeutic appropriateness for which the physician was contacted to recommend a specific course of action was approximately $6.
Frequencies of Combinations of Potential Problems and Actions To Resolve Problems

Discussion
This study demonstrates that it is possible to define categories of pharmacist counseling services that meet the basic requirements of a fee-forservice payment system. Only nine problem-action clusters were required to cover 98% of the encounters reported. Less than 2% of the encounters involved referrals or sending physician communication forms. These nine problem-action clusters were defined on the basis of verifiable and clinically relevant problems and pharmacist actions. The pharmacist time required for each of these services differed significantly from that for the "baseline" service involving a drug monitoring problem requiring patient contact at the time of dispensing. Therefore, a simple resource-based reimbursement system for pharmacist counseling appears to be feasible. At present, pharmacists are compensated only for dispensing medications. Patient counseling in the community pharmacy setting will suffer unless community pharmacies and managed care organizations develop a method for reimbursing pharmacists for these services. While these services do consume pharmacist time, they decrease overall costs for managed care organizations. 16, 21, 31 This study has two important limitations. First, it relies on data collected during the Kaiser Permanente/ USC Patient Consultation Study, which sought to document the extent to which counseling affected health care costs, patient quality of life, and satisfaction with pharmaceutical services; only limited resources were devoted to the collection of data on secondary endpoints, such as pharmacist time required to provide counseling. Second, the reporting requirements varied across the different counseling models in order to minimize the reporting burden on the pharmacists and reduce the impact of data collection on counseling services. Consequently, the validity and reliability of the data used for this analysis cannot be fully verified.
The results of this study should not be used to set prices for pharmacist counseling; rather, they document that a workable fee-for-service system is feasible if sufficient additional research is undertaken. The methods presented here provide an outline for defining PADs for future research. However, the encounter forms used in the KP study did not require pharmacists to record data for recommendations that did not fit the criteria specified in Figure 1 . These other services may be important, because they may consume an inordinate amount of pharmacist time.
Future research will require much more thorough data collection and analysis, such as that required to sup- port Medicare's implementation of the resource-based relative-value scale payment system for physician services. 5 We made no effort to assess the time cost for ancillary personnel or the cost of the capital equipment needed to provide counseling. The KP pharmacist is supported by an extensive computer system that provides up-to-date prescription drug profiles and laboratory test results. Providing comparable information systems in the typical community pharmacy would represent a significant investment. Additional data should be collected with which to expand the PADs we used, including type of medication dispensed, severity of illness, and patient characteristics and comorbidities. Finally, the methods used here to collapse the original 300 PADs into a workable set of services were based on professional judgment and were relatively simplistic. The methods should be more structured in future research, especially if data on additional categorization variables are collected. For example, a classification system based on problem, drug class, action, and disposition would soon become too complex to collapse by using professional judgment.
The variance explained by the model in Table 5 is relatively low (R 2 = 0.0686). This implies that a significant proportion of the variation in pharmacist time requirements across encounters cannot be explained by the proposed problem-action classification system. The explanatory power of the analysis will be stronger if research is based on a more detailed description of the services provided and more accurate timeand-motion data. However, a low R 2 value does not necessarily invalidate the use of regression analysis for identifying problem-action clusters for the purpose of establishing differential payments. Most pharmacies fill thousands of prescriptions during a year, reducing the likelihood that any one pharmacy's average time expended for each type of encounter would vary significantly from the mean estimated with a regression model. However, pharmacies that treat more severely ill populations may not be adequately compensated under this approach.
Conclusion
A fee-for-service payment system appears to be feasible for pharmacist counseling services. Further research efforts are needed to support the implementation of such payment systems likely in conjunction with competitive contracting methods. 
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